We hypothesize that in more than 50% of CLL cases where CD150 and CD180 are coexpressed simultaneous ligation of these receptors on malignant CLL B cells may result in inhibition of pro-survival Akt and MAPK signaling pathways. Here, SLAMF1 is linked to B-cell chronic lymphocytic leukemia.